After several chemotherapy regimens, 1 × 1010 CAR-T cells targeting ERBB2, which has been found to be overexpressed in several different cancers including colon cancer, were used as the fourth line of treatment. This evidence concerns the gene ERBB2 and malignant colon neoplasm.